A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who w...
Ausführliche Beschreibung
Autor*in: |
Zhiqing Chen [verfasserIn] Binbin Chen [verfasserIn] Peike Hu [verfasserIn] Haipeng Liu [verfasserIn] Dingchang Zheng [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Advances in Ophthalmology Practice and Research - Elsevier, 2022, 2(2022), 2, Seite 100051- |
---|---|
Übergeordnetes Werk: |
volume:2 ; year:2022 ; number:2 ; pages:100051- |
Links: |
---|
DOI / URN: |
10.1016/j.aopr.2022.100051 |
---|
Katalog-ID: |
DOAJ040982319 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ040982319 | ||
003 | DE-627 | ||
005 | 20230308042845.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.aopr.2022.100051 |2 doi | |
035 | |a (DE-627)DOAJ040982319 | ||
035 | |a (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RE1-994 | |
100 | 0 | |a Zhiqing Chen |e verfasserin |4 aut | |
245 | 1 | 2 | |a A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. | ||
650 | 4 | |a Dark adaptation | |
650 | 4 | |a Diabetic macular edema | |
650 | 4 | |a Diabetic retinopathy | |
650 | 4 | |a Photobiomodulation | |
650 | 4 | |a Rod cells | |
653 | 0 | |a Ophthalmology | |
700 | 0 | |a Binbin Chen |e verfasserin |4 aut | |
700 | 0 | |a Peike Hu |e verfasserin |4 aut | |
700 | 0 | |a Haipeng Liu |e verfasserin |4 aut | |
700 | 0 | |a Dingchang Zheng |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Advances in Ophthalmology Practice and Research |d Elsevier, 2022 |g 2(2022), 2, Seite 100051- |w (DE-627)1789916518 |x 26673762 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2022 |g number:2 |g pages:100051- |
856 | 4 | 0 | |u https://doi.org/10.1016/j.aopr.2022.100051 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2667376222000282 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2667-3762 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 2 |j 2022 |e 2 |h 100051- |
author_variant |
z c zc b c bc p h ph h l hl d z dz |
---|---|
matchkey_str |
article:26673762:2022----::peiiaybevtoordelhtboouainnraig |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
RE |
publishDate |
2022 |
allfields |
10.1016/j.aopr.2022.100051 doi (DE-627)DOAJ040982319 (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b DE-627 ger DE-627 rakwb eng RE1-994 Zhiqing Chen verfasserin aut A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells Ophthalmology Binbin Chen verfasserin aut Peike Hu verfasserin aut Haipeng Liu verfasserin aut Dingchang Zheng verfasserin aut In Advances in Ophthalmology Practice and Research Elsevier, 2022 2(2022), 2, Seite 100051- (DE-627)1789916518 26673762 nnns volume:2 year:2022 number:2 pages:100051- https://doi.org/10.1016/j.aopr.2022.100051 kostenfrei https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b kostenfrei http://www.sciencedirect.com/science/article/pii/S2667376222000282 kostenfrei https://doaj.org/toc/2667-3762 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2022 2 100051- |
spelling |
10.1016/j.aopr.2022.100051 doi (DE-627)DOAJ040982319 (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b DE-627 ger DE-627 rakwb eng RE1-994 Zhiqing Chen verfasserin aut A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells Ophthalmology Binbin Chen verfasserin aut Peike Hu verfasserin aut Haipeng Liu verfasserin aut Dingchang Zheng verfasserin aut In Advances in Ophthalmology Practice and Research Elsevier, 2022 2(2022), 2, Seite 100051- (DE-627)1789916518 26673762 nnns volume:2 year:2022 number:2 pages:100051- https://doi.org/10.1016/j.aopr.2022.100051 kostenfrei https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b kostenfrei http://www.sciencedirect.com/science/article/pii/S2667376222000282 kostenfrei https://doaj.org/toc/2667-3762 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2022 2 100051- |
allfields_unstemmed |
10.1016/j.aopr.2022.100051 doi (DE-627)DOAJ040982319 (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b DE-627 ger DE-627 rakwb eng RE1-994 Zhiqing Chen verfasserin aut A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells Ophthalmology Binbin Chen verfasserin aut Peike Hu verfasserin aut Haipeng Liu verfasserin aut Dingchang Zheng verfasserin aut In Advances in Ophthalmology Practice and Research Elsevier, 2022 2(2022), 2, Seite 100051- (DE-627)1789916518 26673762 nnns volume:2 year:2022 number:2 pages:100051- https://doi.org/10.1016/j.aopr.2022.100051 kostenfrei https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b kostenfrei http://www.sciencedirect.com/science/article/pii/S2667376222000282 kostenfrei https://doaj.org/toc/2667-3762 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2022 2 100051- |
allfieldsGer |
10.1016/j.aopr.2022.100051 doi (DE-627)DOAJ040982319 (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b DE-627 ger DE-627 rakwb eng RE1-994 Zhiqing Chen verfasserin aut A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells Ophthalmology Binbin Chen verfasserin aut Peike Hu verfasserin aut Haipeng Liu verfasserin aut Dingchang Zheng verfasserin aut In Advances in Ophthalmology Practice and Research Elsevier, 2022 2(2022), 2, Seite 100051- (DE-627)1789916518 26673762 nnns volume:2 year:2022 number:2 pages:100051- https://doi.org/10.1016/j.aopr.2022.100051 kostenfrei https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b kostenfrei http://www.sciencedirect.com/science/article/pii/S2667376222000282 kostenfrei https://doaj.org/toc/2667-3762 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2022 2 100051- |
allfieldsSound |
10.1016/j.aopr.2022.100051 doi (DE-627)DOAJ040982319 (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b DE-627 ger DE-627 rakwb eng RE1-994 Zhiqing Chen verfasserin aut A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells Ophthalmology Binbin Chen verfasserin aut Peike Hu verfasserin aut Haipeng Liu verfasserin aut Dingchang Zheng verfasserin aut In Advances in Ophthalmology Practice and Research Elsevier, 2022 2(2022), 2, Seite 100051- (DE-627)1789916518 26673762 nnns volume:2 year:2022 number:2 pages:100051- https://doi.org/10.1016/j.aopr.2022.100051 kostenfrei https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b kostenfrei http://www.sciencedirect.com/science/article/pii/S2667376222000282 kostenfrei https://doaj.org/toc/2667-3762 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2022 2 100051- |
language |
English |
source |
In Advances in Ophthalmology Practice and Research 2(2022), 2, Seite 100051- volume:2 year:2022 number:2 pages:100051- |
sourceStr |
In Advances in Ophthalmology Practice and Research 2(2022), 2, Seite 100051- volume:2 year:2022 number:2 pages:100051- |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells Ophthalmology |
isfreeaccess_bool |
true |
container_title |
Advances in Ophthalmology Practice and Research |
authorswithroles_txt_mv |
Zhiqing Chen @@aut@@ Binbin Chen @@aut@@ Peike Hu @@aut@@ Haipeng Liu @@aut@@ Dingchang Zheng @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
1789916518 |
id |
DOAJ040982319 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ040982319</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308042845.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.aopr.2022.100051</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ040982319</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Zhiqing Chen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dark adaptation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetic macular edema</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetic retinopathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Photobiomodulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rod cells</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Binbin Chen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peike Hu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haipeng Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dingchang Zheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Ophthalmology Practice and Research</subfield><subfield code="d">Elsevier, 2022</subfield><subfield code="g">2(2022), 2, Seite 100051-</subfield><subfield code="w">(DE-627)1789916518</subfield><subfield code="x">26673762</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:100051-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.aopr.2022.100051</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2667376222000282</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2667-3762</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">100051-</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Zhiqing Chen |
spellingShingle |
Zhiqing Chen misc RE1-994 misc Dark adaptation misc Diabetic macular edema misc Diabetic retinopathy misc Photobiomodulation misc Rod cells misc Ophthalmology A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
authorStr |
Zhiqing Chen |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1789916518 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RE1-994 |
illustrated |
Not Illustrated |
issn |
26673762 |
topic_title |
RE1-994 A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema Dark adaptation Diabetic macular edema Diabetic retinopathy Photobiomodulation Rod cells |
topic |
misc RE1-994 misc Dark adaptation misc Diabetic macular edema misc Diabetic retinopathy misc Photobiomodulation misc Rod cells misc Ophthalmology |
topic_unstemmed |
misc RE1-994 misc Dark adaptation misc Diabetic macular edema misc Diabetic retinopathy misc Photobiomodulation misc Rod cells misc Ophthalmology |
topic_browse |
misc RE1-994 misc Dark adaptation misc Diabetic macular edema misc Diabetic retinopathy misc Photobiomodulation misc Rod cells misc Ophthalmology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Advances in Ophthalmology Practice and Research |
hierarchy_parent_id |
1789916518 |
hierarchy_top_title |
Advances in Ophthalmology Practice and Research |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1789916518 |
title |
A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
ctrlnum |
(DE-627)DOAJ040982319 (DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b |
title_full |
A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
author_sort |
Zhiqing Chen |
journal |
Advances in Ophthalmology Practice and Research |
journalStr |
Advances in Ophthalmology Practice and Research |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
100051 |
author_browse |
Zhiqing Chen Binbin Chen Peike Hu Haipeng Liu Dingchang Zheng |
container_volume |
2 |
class |
RE1-994 |
format_se |
Elektronische Aufsätze |
author-letter |
Zhiqing Chen |
doi_str_mv |
10.1016/j.aopr.2022.100051 |
author2-role |
verfasserin |
title_sort |
preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
callnumber |
RE1-994 |
title_auth |
A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
abstract |
Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. |
abstractGer |
Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. |
abstract_unstemmed |
Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema |
url |
https://doi.org/10.1016/j.aopr.2022.100051 https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b http://www.sciencedirect.com/science/article/pii/S2667376222000282 https://doaj.org/toc/2667-3762 |
remote_bool |
true |
author2 |
Binbin Chen Peike Hu Haipeng Liu Dingchang Zheng |
author2Str |
Binbin Chen Peike Hu Haipeng Liu Dingchang Zheng |
ppnlink |
1789916518 |
callnumber-subject |
RE - Ophthalmology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.aopr.2022.100051 |
callnumber-a |
RE1-994 |
up_date |
2024-07-03T17:48:06.719Z |
_version_ |
1803581009921310720 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ040982319</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308042845.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.aopr.2022.100051</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ040982319</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeef05c29a3ed49f3b5035697b8a9d48b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Zhiqing Chen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P < 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dark adaptation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetic macular edema</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetic retinopathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Photobiomodulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rod cells</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Binbin Chen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peike Hu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haipeng Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dingchang Zheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Ophthalmology Practice and Research</subfield><subfield code="d">Elsevier, 2022</subfield><subfield code="g">2(2022), 2, Seite 100051-</subfield><subfield code="w">(DE-627)1789916518</subfield><subfield code="x">26673762</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:100051-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.aopr.2022.100051</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eef05c29a3ed49f3b5035697b8a9d48b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2667376222000282</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2667-3762</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">100051-</subfield></datafield></record></collection>
|
score |
7.400075 |